Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 45

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 45
---
2025, approximately
0.002% of our outstanding Ordinary Shares was held by registered shareholders with addresses in the United Kingdom, and we had 189 holders
of record in the United Kingdom (in each case, excluding shares held by the custodian under our depositary agreement with JPMorgan Chase
Bank, N.A.). As of April 1, 2025, JPMorgan Chase Bank, N.A., as depositary for the Depositary Shares, held 25,323,852,427 Ordinary Shares,
representing 98.9% of the issued share capital held at that date. As of April 1, 2025, we had five holders of record with an address in
the United States. The number of holders of record or registered holders in the United States or United Kingdom is not representative
of the number of beneficial holders or of the residence of beneficial holders.

Based on our share register,
we believe that we are not directly or indirectly controlled by another corporation or government, or by any other natural or legal persons.
There are no arrangements that may result in a change of control. Our major shareholders do not have different voting rights than other
holders of our Ordinary Shares.

To our knowledge, other than
due to the expiration of unexercised warrants held by our shareholders or as otherwise disclosed elsewhere in, or incorporated by reference
into, this prospectus, there has been no significant change in the percentage ownership of our Ordinary Shares held by the principal shareholders
listed above in the last three years.

| 27 |

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

We
are offering Units, each Unit consisting of one Depositary Share and one Series L Warrant to purchase one Depositary Share. We are also
offering to each purchaser whose purchase of Depositary Shares in this offering would otherwise result in the purchaser, together with
its affiliates, beneficially owning more than 4.99% (or, at the election of the purchaser, up to 9.99%) of our outstanding Ordinary Shares
immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Units containing
Pre-Funded Warrants in lieu of the Depositary Shares that would otherwise result in the purchaser’s beneficial ownership exceeding
4.99% (or, at the election of the purchaser, up to 9.99%) of our outstanding Depositary Shares. For each Pre-Funded Unit we sell